Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1545-1552

  Ünsal, Cüneyt ^a   Albayrak, Yakup ^a   Albayrak, Neslihan ^b   Kuloǧlu, Murat ^c   Hashimoto, Kenji ^d  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

^b K rklareli Training and Research Hospital   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Dyslipidemia; LDL C; Metabolic; Second generation antipsychotics; SGA

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE;

ADULT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; REVIEW; SCHIZOPHRENIA;

EID: 84885904056     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S52463     Document Type: Review

References (54)

1. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393-406.
2. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006;20(4):293-301.
3. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 68(Suppl 1):20-27.
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
5. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1-17.
6. Meyer JM. Cardiovascular illness and hyperlipidemia in patients with schizophrenia. In: Meyer JM, Nasrallah HA, editors. Medical Illness and Schizophrenia. Washington, DC: American Psychiatric Publishing; 2003:50-83.
7. Le Fevre PD. Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism? Scott Med J. 2001;46(1):11-13.
8. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290(4):502-510.
9. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996;33(3):498-507.
10. Gan KN, Smolen A, Eckerson HW, and La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1991;19(1):100-106.
11. Osaki F, Ikeda Y, Suehiro T, et al. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis. 2004;176(2):279-287.
12. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet. 2001;68(6): 1428-1436.
13. Schrader C, Rimbach G. Determinants of paraoxonase 1 status: genes, drugs and nutrition. Curr Med Chem. 2011;18(36):5624-5643.
14. Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci. 2012;4(11):523-532.
15. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008; 13(1):27-35.
16. American Psychiatric Association, editor. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Publishing; 2000.
17. Corapcioglu A, Aydemir O, Yildiz M. DSM-IV Structured Clinical Interview for DSM-IV (SCID-IV), Turkish Version (Turkish). Ankara, Turkey: Hekimler Yayin Birligi; 1999.
18. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Publishing; 1996.
19. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci. 2009;46(2):83-106.
20. Isik A, Koca SS, Ustundag B, Celik H, Yildirim A. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol. 2007;26(3): 342-348.
21. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112-119.
22. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103-1111.
23. Davidson M. Can premorbid and prodromal markers associated with psychosis be utilized for early detection and secondary prevention of schizophrenia? Dialogues Clin Neurosci. 2001;3(2):138-143.
24. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1-2):21-28.
25. Bouchard RH, Demers MF, Simoneau I, et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol. 2001;21(1):110-111.
26. Atmaca M, Kuloglu M, Tezcan, Gecici O. Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res. 2003;60(1):99-100.
27. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64(5):598-604.
28. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63(10):856-865.
29. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5): 425-433.
30. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59(11):1021-1026.
31. Nasrallah HA, Perry CL, Love E, Nasrallah AT. Are there ethnic differences in hypertriglyceridemia secondary to olanzapine treatment. Poster presented at 40th Annual Meeting of the American College of Neuropsychopharmacology; December 10, 2001; Waikoloa, Hawaii.
32. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry. 2001;62(Suppl 27):27-34.
33. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry. 1999;156(9):1471-1472.
34. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60(11):767-770.
35. Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol. 2012;22(2):157-165.
36. Kaushal J, Bhutani G, Gupta R. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone. Singapore Med J. 2012;53(7):488-492.
37. Shao P, Ou J, Wu R, et al. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013;38(4):365-369. Chinese.
38. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother. 2002;3(12):1773-1781.
39. Lee E, Chow LY, Leung CM. Metabolic profile of first and second generation antipsychotics among Chinese patients. Psychiatry Res. 2011;185(3):456-458.
40. Moreno C, Merchán-Naranjo J, Alvarez M, et al. Metabolic effects of second generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord. 2010; 12(2):172-184.
41. Hu S, Yao M, Peterson BS, et al. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients. Psychopharmacology (Berl). Epub April 5, 2013.
42. Bobo WV, Epstein RA, Shelton RC. Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial. Hum Psychopharmacol. 2010;25(1):30-36.
43. Newcomer JW, Meyer JM, Baker RA, et al. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr Res. 2008;106(2-3):300-307.
44. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. 2001;24(1):59-73.
45. Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatry. 2002;41(5): 495-496.
46. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21(4):369-374.
47. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol. 2001;11(4):415-424.
48. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006;14(3):152-164.
49. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001;42(3):181-188.
50. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156(11):1686-1696.
51. Gungor O, Kircelli F, Demirci MS, et al. Serum paraoxonase 1 activity predicts arterial stiffness in renal transplant recipients. J Atheroscler Thromb. 2011;18(10):901-905.
52. Wang Y, Fu W, Xie F, et al. Common polymorphisms in ITGA2, PON1 and THBS2 are associated with coronary atherosclerosis in a candidate gene association study of the Chinese Han population. J Hum Genet. 2010;55(8):490-494.
53. Wang M, Lang X, Cui S, et al. Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk. DNA Cell Biol. 2012;31(6):975-982.
54. Zhao Y, Ma Y, Fang Y, et al. Association between PON1 activity and coronary heart disease risk: A metaanalysis based on 43 studies. Mol Genet Metab. 2012;105(1):141-148.